Compare Apple Inc (AAPL) vs Mesoblast Limited (MESO) Price & Performance

AAPL trades at $312.66, up 1.31% on the day, with a bullish technical signal and strong fundamentals. The company reported Q1 2026 EPS of $2.01, beating expectations, and maintains robust profitability with a 27.15% net income margin. Recent news highlights Apple's AI strategy leveraging its 2.5 billion active devices, though it faces scrutiny over a unionized store closure.

Outlook remains positive with a consensus price target of $329.62, offering ~5% upside. Key risks include potential Q2 2026 earnings miss on weaker iPhone sales and regulatory pressures. Institutional activity shows mixed signals, but analyst consensus is 63% buy, supporting a favorable risk-reward profile for long-term investors.

MESO trades at $14.33, down 0.35% with a bearish technical signal. The company reported Q1 2025 revenue of $17.20M with a gross margin of 80.52% but significant losses (-$102.14M net income). Recent developments include FDA BLA filing for rexlemestrocel-L in heart failure and a $50M debt facility draw. Analyst consensus shows 45% buy ratings amid high valuation multiples (P/S 30.52).

Outlook hinges on regulatory approvals and commercial execution. The stock offers speculative upside from pipeline catalysts but carries substantial risk from cash burn and clinical trial outcomes. Investors face volatility from binary regulatory events while current fundamentals reflect pre-revenue biotech challenges.